--- title: "Pliant Therapeutics (PLRX) stock: news and investor profile" url: "https://aibio.space/companies/pliant-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Pliant Therapeutics, Inc. (NASDAQ: PLRX), United States. The directory classifies it as Biotechnology." --- PLRX Pliant Therapeutics, Inc. NASDAQ · United States # Pliant Therapeutics (PLRX) news Distress · 2025-05-01 ## [Pliant Therapeutics to cut workforce by about 45%, expects $3.6 million in severance costs](https://aibio.space/news/pliant-therapeutics-cut-workforce-about-45-percent-expects-3-6-million/) Pliant expects to substantially complete the reduction by the end of the second quarter of 2025, with about $3.6 million in severance and related benefits. The cut follows the discontinuation of its BEACON-IPF Phase 2b trial of bexotegrast. ## Latest Pliant Therapeutics news 1. 2025-03-13 Mergers [Pliant Therapeutics, Inc. adopts stockholder rights plan with $12.64 exercise price](https://aibio.space/news/pliant-therapeutics-inc-adopts-stockholder-rights-plan-12-64-exercise/) Pliant's board adopted a limited-duration rights plan on March 12, 2025, citing recent accumulations of its common stock. The rights trigger at 10% ownership, or 20% for certain passive investors, and expire on March 11, 2026. 2. 2025-03-13 Mergers [Pliant Therapeutics adopts one-year shareholder rights plan after stock buildup](https://aibio.space/news/pliant-therapeutics-adopts-one-year-shareholder-rights-plan-after/) Pliant's board adopted a one-year stockholder rights plan, and the company's trigger is a 10% stake bought without board approval. The release cites unspecified "recent accumulations" of stock and does not name who was buying, less than two weeks after its annual report disclosed the discontinuation of its lead Phase 2b trial. ## Pliant Therapeutics at a glance - **Ticker**: PLRX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $158.1 million ### Related companies - [Syndax Pharmaceuticals](https://aibio.space/companies/syndax-pharmaceuticals/) NASDAQ: SNDX - [ANI Pharmaceuticals](https://aibio.space/companies/ani-pharmaceuticals/) NASDAQ: ANIP - [Gain Therapeutics](https://aibio.space/companies/gain-therapeutics/) NASDAQ: GANX - [CG Oncology](https://aibio.space/companies/cg-oncology/) NASDAQ: CGON - [Adaptive Biotechnologies](https://aibio.space/companies/adaptive-biotechnologies/) NASDAQ: ADPT - [Benitec Biopharma](https://aibio.space/companies/benitec-biopharma/) NASDAQ: BNTC - [Tvardi Therapeutics](https://aibio.space/companies/tvardi-therapeutics/) NASDAQ: TVRD - [Caribou Biosciences](https://aibio.space/companies/caribou-biosciences/) NASDAQ: CRBU ### Also on NASDAQ - [Alkermes](https://aibio.space/companies/alkermes/) ALKS - [Lisata Therapeutics](https://aibio.space/companies/lisata-therapeutics/) LSTA - [Cartesian Therapeutics](https://aibio.space/companies/cartesian-therapeutics/) RNAC - [Kamada](https://aibio.space/companies/kamada/) KMDA - [Crescent Biopharma](https://aibio.space/companies/crescent-biopharma/) CBIO - [MANNATECH INC](https://aibio.space/companies/mannatech/) MTEX ## What Pliant Therapeutics does Pliant Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops integrin-based therapeutics. Its lead program aims at solid tumors by inhibiting integrin-mediated activation of transforming growth factor-beta (TGF-β). Its wholly owned lead candidate, PLN-101095, is an oral small molecule dual selective inhibitor of αvβ8 and αvβ1 integrins for solid tumors that are resistant to immune checkpoint inhibitors. The company describes TGF-β as a potential cause of checkpoint inhibitor resistance and aims to sensitize tumors to checkpoint inhibitors. It announced positive Phase 1 open-label dose-escalation data in March 2025 and December 2025, in which PLN-101095 was given as monotherapy for 14 days followed by pembrolizumab. Across the three highest dose cohorts, there were four responders among 10 secondary ICI refractory patients. The company also maintains a proprietary library of over 15,000 integrin binding molecules for targeted drug delivery. | Product or program | What it is | Stage | |---|---|---| | PLN-101095 | Oral dual inhibitor of αvβ8 and αvβ1 integrins for solid tumors resistant to immune checkpoint inhibitors | Phase 1 open-label dose-escalation data reported in 2025 | Summarised from the company's [10-K filed Mar 11, 2026](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm). ## Pliant Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/) | [$0](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/) | | Research and development | [$109.2 million](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/) | [$169.3 million](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/) | | Net income (loss) | [-$149.3 million](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/) | [-$210.3 million](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/) | | Cash from operations | [-$128.3 million](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/) | [-$155.5 million](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/) | | Cash and equivalents | [$45.4 million](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000113/) | [$71.2 million](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/) | | Short-term investments | [$145.5 million](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000113/) | [$284.5 million](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $24.9 million, plus short-term investments of $133.2 million, $158.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Pliant Therapeutics What is the ticker symbol of Pliant Therapeutics? Pliant Therapeutics, Inc. trades under the ticker PLRX on NASDAQ. Where is Pliant Therapeutics listed? Pliant Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:9PT; LS:A2P4YV. What is the SEC CIK of Pliant Therapeutics? The SEC Central Index Key (CIK) for Pliant Therapeutics, Inc. is 1746473. Its filings are on SEC EDGAR. How many shares does Pliant Therapeutics have outstanding? 61,921,897 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Pliant Therapeutics listed under? Our directory records Pliant Therapeutics, Inc. under United States. What does Pliant Therapeutics do? Our directory classifies Pliant Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Pliant Therapeutics? The ISIN recorded for Pliant Therapeutics, Inc. is US7291391057. Does aibio.space cover Pliant Therapeutics? aibio.space lists Pliant Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Pliant Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Pliant Therapeutics develop? Pliant Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops integrin-based therapeutics. Its lead program aims at solid tumors by inhibiting integrin-mediated activation of transforming growth factor-beta (TGF-β). What is PLN-101095 from Pliant Therapeutics? PLN-101095: Oral dual inhibitor of αvβ8 and αvβ1 integrins for solid tumors resistant to immune checkpoint inhibitors Stage: Phase 1 open-label dose-escalation data reported in 2025. What was Pliant Therapeutics's revenue last year? $0 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Pliant Therapeutics profitable? Pliant Therapeutics, Inc. reported a net loss of $149.3 million for the fiscal year ended Dec 31, 2025, and used $128.3 million of cash in operations, per its annual report to the SEC. How much does Pliant Therapeutics spend on research and development? $109.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Pliant Therapeutics have? $158.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Pliant Therapeutics Members talk about Pliant Therapeutics (PLRX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Pliant Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-03-30 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1746473/000119312526131933/d130516ds3.htm) 2. 2025-10-20 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1746473/000119312525243619/d14014d8k.htm) 3. 2025-05-01 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02). [Source](https://www.sec.gov/Archives/edgar/data/1746473/000119312525109976/d949809d8k.htm) 4. 2025-03-13 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1746473/000119312525053541/d815684dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PLRX on TradingView](https://www.tradingview.com/symbols/NASDAQ-PLRX/). ## SEC filings and registration - **SEC name**: Pliant Therapeutics, Inc. - **CIK**: 1746473 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PLRX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: 650-481-6770 - **Shares outstanding**: 61,921,897 as of 2026-08-07 (10-Q filed 2026-08-11) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000115/plrx-20260811.htm) filed 2026-08-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000113/plrx-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000107/plrx-20260709.htm) filed 2026-07-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000092/plrx-20260611.htm) filed 2026-06-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000090/plrx-20260331.htm) filed 2026-05-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000088/plrx-20260511.htm) filed 2026-05-11 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000076/plrx-20260422.htm) filed 2026-04-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000050/plrx-20260414.htm) filed 2026-04-17 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001746473), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Pliant Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PLRX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Pliant Therapeutics, Inc. - **Ticker**: PLRX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US7291391057 - **Other listed symbols**: GETTEX:9PT; LS:A2P4YV - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PLRX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/pliant-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Pliant Therapeutics (PLRX) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/pliant-therapeutics/